Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Gastroenterologist Dr Salhab warns that liver cirrhosis can lead to overt hepatic encephalopathy, impacting brain function ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

Serious infections significantly increase the mortality risk among adults with chronic liver disease, including those without cirrhosis.

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

In hospitalized patients with acute kidney injury and liver cirrhosis, baseline and peak levels of serum cystatin C can ...

Cirrhosis, a chronic liver disease, results from long-term damage and scarring, impairing vital functions. Common causes include alcohol abuse, hepatitis, and fatty liver disease. Early detection ...

New research in JAMA Internal Medicine has challenged the current guideline recommending 5-7 days of preventive antibiotics ...

Current guidelines for patients with cirrhosis and upper-GI bleeding recommend 5 to 7 days of antibiotic prophylaxis to ...